Literature DB >> 8077050

Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells.

Y Liu1, M Heyman, Y Wang, U Falkmer, C Hising, L Székely, S Einhorn.   

Abstract

Loss of heterozygosity (LOH) at the site of the retinoblastoma (RB1) gene, at 13q14, has been shown to occur in a high proportion of ovarian cancer patients. Based on this, RB1 gene inactivation was studied in primary tumor cells from 15 patients with ovarian cancer. Structural changes as well as expression of the RB1 gene were investigated. One patient had a nondisjunctional deletion at the RB1 locus, and the duplicated remaining allele carried a deletion of exon 21. In another patient, without detectable structural changes of the RB1 gene, no RB protein was detected. Allelic losses at the RB1 locus were observed in 8/13 informative cases (61%). Our results indicate that inactivation of the RB1 gene plays a role in tumor development in a minority of ovarian cancer patients. Another gene(s) on 13q also seem(s) to influence malignant transformation in patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077050     DOI: 10.1002/ijc.2910580508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

Review 2.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer.

Authors:  A J Alvi; R Hogg; J S Rader; M J Kuo; E R Maher; F Latif
Journal:  Mol Pathol       Date:  2002-06

4.  Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.

Authors:  C Ceccarelli; D Santini; P Chieco; M Taffurelli; M Gamberini; S A Pileri; D Marrano
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

5.  Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.

Authors:  A P M Jongsma; J M J Piek; R P Zweemer; R H M Verheijen; J W T Klein Gebbinck; G J van Kamp; I J Jacobs; P Shaw; P J van Diest; P Kenemans
Journal:  Mol Pathol       Date:  2002-10

Review 6.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16.

Authors:  Maria C Todd; Thomas A Langan; Robert A Sclafani
Journal:  J Cancer       Date:  2017-01-13       Impact factor: 4.207

Review 8.  Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.

Authors:  Z Ping Lin; Yong-Lian Zhu; Elena S Ratner
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

9.  APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Authors:  Rachel Brough; Ilirjana Bajrami; Radost Vatcheva; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth
Journal:  EMBO J       Date:  2012-01-31       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.